Related references
Note: Only part of the references are listed.Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews
Chantelle Garritty et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)
Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant
Kokuvi Atsou et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
Paul E. Greenberg et al.
PHARMACOECONOMICS (2021)
The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States A Decision Analytic Model
Eric L. Ross et al.
ANNALS OF INTERNAL MEDICINE (2019)
Economic evidence for the clinical management of major depressive disorder: a systematic review and quality appraisal of economic evaluations alongside randomised controlled trials
E. Karyotaki et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2017)
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
Erkki Soini et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2017)
Cost-Effective Drug Switch Options After Unsuccessful Treatment With an SSRI for Depression
Ashima Singh et al.
PSYCHIATRIC SERVICES (2017)
Evaluating the economic impact of screening and treatment for depression in the workplace
Sara Evans-Lacko et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Scaling-up treatment of depression and anxiety: a global return on investment analysis
Dan Chisholm et al.
LANCET PSYCHIATRY (2016)